Fan_2023_Mol.Cell_83_3520

Reference

Title : Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy - Fan_2023_Mol.Cell_83_3520
Author(s) : Fan Y , Gao Y , Nie L , Hou T , Dan W , Wang Z , Liu T , Wei Y , Wang Y , Liu B , Que T , Lei Y , Zeng J , Ma J , Wei W , Li L
Ref : Mol Cell , 83 :3520 , 2023
Abstract :

Cyclic GMP-AMP synthase (cGAS) binds pathogenic and other cytoplasmic double-stranded DNA (dsDNA) to catalyze the synthesis of cyclic GMP-AMP (cGAMP), which serves as the secondary messenger to activate the STING pathway and innate immune responses. Emerging evidence suggests that activation of the cGAS pathway is crucial for anti-tumor immunity; however, no effective intervention method targeting cGAS is currently available. Here we report that cGAS is palmitoylated by ZDHHC9 at cysteines 404/405, which promotes the dimerization and activation of cGAS. We further identified that lysophospholipase-like 1 (LYPLAL1) depalmitoylates cGAS to compromise its normal function. As such, inhibition of LYPLAL1 significantly enhances cGAS-mediated innate immune response, elevates PD-L1 expression, and enhances anti-tumor response to PD-1 blockade. Our results therefore reveal that targeting LYPLAL1-mediated cGAS depalmitoylation contributes to cGAS activation, providing a potential strategy to augment the efficacy of anti-tumor immunotherapy.

PubMedSearch : Fan_2023_Mol.Cell_83_3520
PubMedID: 37802025
Gene_locus related to this paper: human-LYPLAL1

Related information

Inhibitor Lyplal1-IN-1
Gene_locus Lyplal1-IN-1    human-LYPLAL1

Citations formats

Fan Y, Gao Y, Nie L, Hou T, Dan W, Wang Z, Liu T, Wei Y, Wang Y, Liu B, Que T, Lei Y, Zeng J, Ma J, Wei W, Li L (2023)
Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy
Mol Cell 83 :3520

Fan Y, Gao Y, Nie L, Hou T, Dan W, Wang Z, Liu T, Wei Y, Wang Y, Liu B, Que T, Lei Y, Zeng J, Ma J, Wei W, Li L (2023)
Mol Cell 83 :3520